Myriad Genetics (MYGN) Tops Q1 EPS by 3c ; Offers Guidance

Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $195.9 million versus the consensus estimate of $200.9 million.

GUIDANCE:

Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of $0.08. Myriad Genetics sees FY2025 revenue of $807-823 million, versus the consensus of $916 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
• DigitalOcean (DOCN) Reiterated at Overweight by Cantor Fitzgerald on Q2 Pre-Announcement
• Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism